CN101496851A - Chinese medicine for treating carcinous pleural fluid and ascites - Google Patents
Chinese medicine for treating carcinous pleural fluid and ascites Download PDFInfo
- Publication number
- CN101496851A CN101496851A CNA2008100102419A CN200810010241A CN101496851A CN 101496851 A CN101496851 A CN 101496851A CN A2008100102419 A CNA2008100102419 A CN A2008100102419A CN 200810010241 A CN200810010241 A CN 200810010241A CN 101496851 A CN101496851 A CN 101496851A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- semen
- pleural fluid
- group
- portions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to a traditional Chinese medicine for treating carcinous breast ascites, and belongs to the field of traditional Chinese medicine. The traditional Chinese medicine consists of the following components in portion by weight: 0.8 to 1.6 portions of artificial calculus bovis, 0.5 to 0.9 portion of laminaria, 0.5 to 0.9 portion of seaweed, 0.5 to 0.9 portion of semen pharbitidis, 0.8 to 1.6 portions of black nightshade, 0.5 to 0.9 portion of cassia kernel, 0.8 to 1.6 portions of semen lepidii, 0.4 to 0.8 portion of pricklyash peel, 0.7 to 1.3 portions of cordyceps, and 0.8 to 1.6 portions of white mustard seed. The traditional Chinese medicine can be prepared into water pills, powder, tablets and granules. The traditional Chinese medicine for treating the carcinous breast ascites can expel effusion in vivo of a patient, relieve the pain of the patient, and prolong the life time of the patient.
Description
Technical field:
The invention belongs to tcm field, relate to a kind of Chinese medicine for the treatment of cancerous ascites pleural fluid specifically.
Background technology:
The traditional Chinese medical science thinks that ascites pleural fluid is the pathological product that water liquid dysbolismus forms, and stays in the position difference of human body according to water liquid, is divided into phlegm retention, hydrothorax, anasarca, fluid-retention in the chest and hypochondrium.The clinical manifestation of hydrothorax card is distension in cough, the side of body, can not put down crouch or ascites pleural fluid one side rib between full, dyspnea.Cure ancient times nationality also this disease of handlebar be referred to as hypochondrium fluid retention, say as " General Treatise on the Cause and Symptoms of Diseases ": " this is by drinking a lot of water, and aqueous vapor stops meeting conflict between pathogenic cold and vital QI between the poly-high rib, and then knot is poly-forms, the meaning hypochondrium fluid retention ".
Cancerous ascites pleural fluid is multiple malignant tumor common complication, clinical treatment mainly is the intracavity chemotherapy at present, or injects immunity anticancer medicine and sclerosing agent, and cooperates diuretic and thoracic drainage and thoracentesis art, but above-mentioned therapy has certain limitation and side effect, has influenced clinical efficacy.
Summary of the invention:
The purpose of this invention is to provide and a kind ofly can dispel hydrops in patient's body, alleviate the patient suffering, prolong the Chinese medicine preparation of the treatment cancerous ascites pleural fluid of patient life cycle; The objective of the invention is to be achieved through the following technical solutions: a kind of Chinese medicine preparation for the treatment of cancerous ascites pleural fluid; it is made up of the component of following parts by weight proportioning: the artificial Calculus Bovis 0.8～1.6; Thallus Laminariae (Thallus Eckloniae) 0.5～0.9, Sargassum 0.5～0.9, Semen Pharbitidis 0.5～0.9; Herba Solani Nigri 0.8～1.6; Cortex Cinnamomi 0.5～0.9, Semen Lepidii (Semen Descurainiae) 0.8～1.6, Semen zanthoxyli 0.4～0.8; Cordyceps 0.7～1.3, Semen Sinapis Albae 0.8～1.6.
The present invention can be made into the watered pill, powder, tablet, granule.
The production method of the watered pill is as follows: get it filled by weight ratio, sterilization is ground in small, broken bitsly, and (pulverize before the abundant drying of medical material) sieves, and mixing is with equivalent incremental method and fine powder mix homogeneously, standby with the artificial Calculus Bovis.
Molding: above-mentioned segmentation, getting 1/5th is wetting agent (8h is with the cold boiled water or the distilled water of interior system) with water, adopts the molding of wet-milling granulation, screening.
Molding: will screen the uniform spherical mould, and strengthen gradually; Promptly add repeatedly on the ball mould water moistening, on powder round as a ball and the screening.
Capping: will strengthen, qualified, screen uniform pill, with the clear water capping, a period of time of rolling, take out drying.
Dry: adopt the natural temperature drying, should be above 60 ℃.
Select ball: dried pill, further filter out pill of the same size, standby.
Pharmacological action:
The artificial Calculus Bovis: the artificial Calculus Bovis processes through extraction for Fel Bovis seu Bubali or Fel Sus domestica, bitter, sweet cold such as liver heart channel, endogenous wind stopping relieving convulsion, waking up the patient from unconsciousness by dissipating phlegm, heat-clearing and toxic substances removing.
Thallus Laminariae (Thallus Eckloniae): salty-cold, return liver stomach kidney channel, effect eliminating phlegm and softening indurated mass, diuretic, clinical practice Thyreoidine cancer, esophageal carcinoma, pulmonary carcinoma, malignant lymphoma.
Sargassum: bitter salty-cold, return the Autoscreen II warp, effect eliminating phlegm and softening indurated mass, diuretic, clinical thyroid carcinoma, breast carcinoma, cervical cancer, the rectal cancer of being used for the treatment of.
Semen Pharbitidis: bitter cold is poisonous, returns lung kidney large intestine channel.It is long-pending to dispel under rushing down, the detumescent of relieving oedema or abdominal distension through diuresis or purgation, parasite killing.Be usually used in the heap soil or fertilizer over and around the roots of the intestines and stomach excess-heat and stagnate, constipation, and aqueous vapor stops holding diseases such as edema abdominal distention.
Herba Solani Nigri: bitter little sweet cold slightly poisonous, go into lung stomach urinary bladder channel, heat-clearing and toxic substances removing, promoting blood circulation and detumescence, diuresis.Cure mainly kinds of tumors, as cervical cancer, gastric cancer, hepatocarcinoma, breast carcinoma, pulmonary carcinoma, cancerous ascites pleural fluid.
Cortex Cinnamomi: hot sweet big heat, return kidney spleen conscience warp, the warming middle-JIAO YANG invigorating, dispersing cold for relieving pain, compatible with the bitter cold diuretic, can help the gasification function of bladder, cinnamic aldehyde has antitumor action, and Oleum Cinnamomi is for oral administration, can strengthen to digest mechanism, rushes down the intestinal pneumatosis.
Semen Lepidii (Semen Descurainiae): toil Great Cold, return the lung urinary bladder channel, effect clearing lung, relieving asthma, inducing diuresis to remove edema.The clinical pulmonary carcinoma that is mainly used in merges ascites pleural fluid, treatment edema, dysuria, accumulation and obstruction of sputum.
Semen zanthoxyli: bitter cold, favourable level is breathed heavily effect, is applicable to the phlegm retention dyspnea with rapid respiration, cards such as edema distension.
Cordyceps: sweet in the mouth acid, property are flat, gas is fragrant, go into the lung kidney channel, can be strong, kidney tonifying lung, tonifying deficiency, beneficial vital essence, detoxifcation, hemostasis and phlegm.
Semen Sinapis Albae: suffering, temperature.Return lung meridian, the warming the lung to eliminate phlegm promoting the circulation of QI: cure mainly the cold-phlegm heap soil or fertilizer over and around the roots and stagnate, cough and asthma, abundant expectoration are rare clearly; Or drink stays the breast side of body, dyspnea with fullness of the chest hypochondriac pain.The promoting the circulation of QI eliminating stagnation, removing obstruction in the collateral to relieve pain: be suitable for the heresy of phlegm retention, multiple abscess meridians, limbs joint pain numbness that causes and carbuncle of yin nature multiple abscess.Often join the logical medicine that stagnates of warming YANG.
The present invention is a principal agent with Calculus Bovis, Semen zanthoxyli; simultaneously using both cold and hot drugs; tonneau is in last effect; with Semen Pharbitidis, Semen Lepidii (Semen Descurainiae) is ministerial drug; have to fall and let out in following effect, assistant is with Herba Solani Nigri, Semen Sinapis Albae, Thallus Laminariae (Thallus Eckloniae), Sargassum line water detumescence, with Cordyceps set upright, eliminating evil; make with the descending unit of returning of Cortex Cinnamomi priming the road that goes out with hyatodontia.Its effect cures mainly: the drink of dispelling of relieving oedema or abdominal distension through diuresis or purgation, and the tonneau three warmers cure mainly cancerous ascites pleural fluid and pericardial effusion, and disease is seen cough with asthma, dyspnea, ascites tympanites, shortness of breath and palpitation.
The test example:
The present invention treats the clinical observation of cancerous ascites pleural fluid:
One, diagnostic criteria
1. Western medicine diagnose standard
Referring to ministry of Health of China Department of Medical Administration " Chinese common cancer diagnosis and treatment standard ".Be diagnosed as the cancerous ascites pleural fluid patient through rabat, CT, color ultrasound, pathology.
2. tcm diagnosis standard
Publishing house publishes referring to " regular higher education Chinese medicine class planning religion mark " Chinese internal medicine Science and Technology of Shanghai.
(1) hydrothorax (fluid-retention in the chest and hypochondrium type): disease is seen expectoration, chest pain, dyspnea, shortness of breath and palpitation, pale tongue or dark tongue quality, deep and stringy pulse.
(2) tympanites (qi-stagnant damp-obstruction type): abdominal distention is big, by wrap up in water as capsule, hypourocrinia, or abdominal distention after meal pain, edema of pair of lower extremities, jaundice, pale tongue or body of the tongue are deep red, greasy fur, stringy and thready pulse or stringy and thready pulse number.
Two, include standard in
1. make a definite diagnosis this patient through X-ray, CT, the ultrasonic pathology that involves.
2. can carry out the objective indicator tester.
3. meet Western medicine diagnose and TCM Syndrome Type diagnosis person.
4. Ka Shi integration 〉=30 minute person.
Three, case goes out the group standard
1. can not carry out objective detection person.
2. adopt other method therapist at this disease.
3. severe cardiac, liver, renal dysfunction or special patient are arranged.
Four, pick out case standard (＜5%)
1. do not meet this research person of including in.
2. unprovoked unsatisfactory curative effect or the untoward reaction person that stops using.
Five, clinical data
1. physical data: observe cancerous ascites pleural fluid 181 examples altogether, treatment group A (treatment by Chinese herbs group) 61 examples, treatment group B (Chinese medicine adds the Western medicine group) 63 examples, matched group C57 example.
Pulmonary carcinoma ascites pleural fluid 168 examples wherein, breast carcinoma ascites pleural fluid 9 examples, malignant thymoma ascites pleural fluid 1 example, malignant lymphoma ascites pleural fluid 1 example, gastric cancer ascites pleural fluid 1 example, intestinal cancer ascites pleural fluid 1 example.Male's 106 examples, women's 75 examples, the oldest 84 years old, minimum 36 years old.
2. grouping and administration:
Require case to meeting to include in, be divided into cancerous ascites pleural fluid treatment by Chinese herbs group (A group) at random, Chinese medicine adds Western medicine group (B group), matched group (C group).
A group: give Chinese medicine the present invention, each 4g, days 3 times are oral.
B group: give Chinese medicine the present invention, add C group medicine.
The C group: intracavitary administration mycobacterium phlei F.U.36 injection 3.44 μ g, cisplatin 80mg, alternately, weekly.
And cooperate and to put ascites pleural fluid and use diuretic, be to compare a course of treatment all around.
3. curative effect determinate standard:
(1) the carcinous transudate curative effect determinate standard of stipulating according to WHO:
CR (alleviating fully): transudate disappears, and continues more than 1 month.
PR (part is alleviated): transudate reduces 〉=50%, continues more than 1 month.
S (stablizing): transudate incomplete absorption 50% continues more than 1 month.
P (deterioration): transudate no change or increase.
(2) life cycle (MST) evaluation criteria:
From treatment begin to death or last with the time of examining.
(3) mild symptoms weight classification standards of grading:
Mild symptoms weight classification grade form
| Symptom | Asymptomatic | One-level (+) | Secondary (++) | Three grades (+++) |
| Cough | Do not have | Be interrupted outbreak | Between firsts and seconds | The frequent influence life of cough |
| Expectoration | Do not have | Expectorant is not with blood less | The medium band blood streak of amount of expectoration | Abundant expectoration band blood volume is many |
| Chest pain | Do not have | Chest pain once in a while | Do during chest pain | Chest pain is acutely frequent |
| Dyspnea | Do not have | Dyspnea but do not influence activity | Dyspnea is moving then more so | Dyspnea can not be put down for sleeping in |
| Shortness of breath and palpitation | Do not have | Breathe hard after the activity | Also feel during rest and breathe hard | The influence of breathing hard is lived |
| The urine amount | Normally | Amount reduces more at ordinary times | Every day urine amount≤1000ml | Every day urine amount＜500ml |
| Picture of the tongue | Light red tongue | Light red tongue or dark tongue quality | Red tongue | Crimson tongue or livid purple |
| Pulse condition | Normally | Heavy thin or stringy and thready pulse | Count accurately | Thin and delicate unable |
By: methods of marking (+++) 3 minutes respectively, (++) 2 minutes, (+) 1 minute, (one) 0 minute, it is significantly to improve that clinical syndrome integrated value descends greater than 2/3, integrated value descends greater than 1/3 be that part is improved less than 2/3, and integrated value does not have and descends or descend less than 1/3 to there not being improvement.
Six, result
The carcinous hydrothorax clinical efficacy contrast of table 1
| Group | The example number | CR | PR | S | P | Effective percentage | The P value |
| A group (treatment by Chinese herbs group) B group (Chinese medicine+western medicine group) C organizes (matched group) | 61 63 57 | 4 8 3 | 24 34 17 | 19 14 18 | 14 7 19 | 45.9％ 66.7％ 35.1％ | >0.05 <0.05 |
A, B group effective percentage all is higher than matched group C, but mainly Chinese medicine+the Western medicine group is evident in efficacy, P＜0.05.
The carcinous hydrothorax survival rate contrast of table 2
| Treatment group A | Effective percentage | Treatment group B | Effective percentage | Matched group C | Effective percentage | |
| 6 months 1 year 2 years 3 years | 61/40 example, 61/16 example, 61/4 example, 61/1 example | 65.6％ 26.2％ 6％ 2％ | 63/49 example, 63/25 example, 63/7 example, 63/2 example | 77.8％ 39.7％ 11.1％ 3％ | 57/23 example, 57/9 example, 57/1 example, 57/0 example | 40.4％ 16％ 2％ 0 |
Treatment group A and B group, survival rate was apparently higher than matched group C in 6 months, survival rate is respectively 65.6%, 77.8%, learn by statistics and handle P＜0.01, but annual rate treatment group A and the matched group no significant difference deposited, have only treatment group B to be higher than matched group C, survival rate treatment group A and B and the equal zero difference P of matched group more than P＜0.05,2 year〉0.05.
The carcinous hydrothorax clinical symptoms of table 3 is improved contrast
As can be seen from Table 3, treatment group A and B group doing well,improving are apparent in view, as cough, expectoration, chest pain, but dyspnea improvement and matched group there was no significant difference (P〉0.05).
Seven, discuss
For the treatment of cancerous ascites pleural fluid, pure oral preparation of Chinese traditional medicinal is not also arranged at present clinically, treating this disease both at home and abroad mainly still is after with closed drainage intracavity body fluid being drained, to inject chemotherapeutic or immunity anticancer medicine, and effect is good than systemic chemotherapy., cancer patient's major part has a delicate constitution, and can not all implement this method.Motherland's medical science has enough knowledge for a long time to cancerous ascites pleural fluid, belongs to traditional Chinese medical science categories such as " hydrothoraxs ".Studying carefully its pathomechanism, mainly is that functions such as lung, spleen, kidney, liver are not normal, and qiactivity of triple energizer is unfavorable, and QI and blood water stasis of blood knot forms.The card that belongs to deficiency in origin and excess in superficiality.Mainly relieve oedema or abdominal distension through diuresis or purgation the method for tonneau three warmers in the treatment with the drink of dispelling.
The present invention adopts Chinese medicine the present invention treatment to 181 routine cancerous ascites pleural fluid patients, and clinical effectiveness is more satisfactory.Wherein treatment group A effective percentage is 45.90%, and treatment group B effective percentage is 66.7%, all is higher than matched group C35.1%, and main Chinese medicine cooperates Western medicine (i.e. treatment group B) evident in efficacy, learns by statistics and handles P＜0.05.From survival rate, carcinous hydrothorax, six months life cycles, no matter treatment group A or treatment group B all were higher than matched group C (P＜0.05), but annual rate treatment group A and the matched group C no significant difference (P〉0.05) deposited, have only treatment group B to be significantly higher than matched group C (P＜0.05), survival rate more than 2 years, treatment group and matched group there are no significant difference.
From clinical symptoms improvement situation, apparently higher than matched group (P＜0.05), but dyspnea improves and matched group there was no significant difference (P〉0.05) for cough, expectoration, chest pain doing well,improving for carcinous hydrothorax, treatment group A and treatment group B.
In the experimentation, select people's pulmonary carcinoma ascites pleural fluid in late period type, people's hepatocarcinoma, human pancreas cancer ascitic type nude mice orthotopic implantation model, carried out the antitumor drug effect and observed.The result shows that the present invention is to human lung adenocarcinoma nude mice orthotopic implantation model: the 6.24g/kg suppression ratio is 54.63%, and the 3.12g/kg suppression ratio is 43.3%, and the 1.56g/kg suppression ratio is 35.9%.To people's hepatocarcinoma nude mice orthotopic implantation model: the 6.24g/kg suppression ratio is 56.8%, and the 3.12g/kg suppression ratio is 47.9%, and the 1.56g/kg suppression ratio is 29.4%.Human pancreas cancer nude mice original position is claimed to plant model: the 6.24g/kg suppression ratio is 60.9%, and the 3.12g/kg suppression ratio is 37.3%, and the 1.56g/kg suppression ratio is 33.5%.Ultrastructural observation result, the present invention act on the cancer cell membrane architecture, make cancer cell membrane structure division dissolved destruction, cause cancerous cell to lose the barrier stent effect, cause cancer cell death, for this medicine clinical practice provides theoretical basis.Clinical practice has illustrated that also simple application the present invention can make a small amount of cancerous ascites pleural fluid absorb fully, cooperate the western medicine effect more obvious, and to the undesirable patient of the effect that discharges water, take and continue several weeks behind this medicine and need not take out ascites pleural fluid, prolong patient's life cycle, improved life quality.Proof treatment by Chinese herbs cancerous ascites pleural fluid has wide practical use.
The specific embodiment:
Embodiment 1: take by weighing raw material by following proportioning: artificial Calculus Bovis 0.8g, Thallus Laminariae (Thallus Eckloniae) 0.5g, Sargassum 0.5g, Semen Pharbitidis 0.5g, Herba Solani Nigri 0.8g, Cortex Cinnamomi 0.5g, Semen Lepidii (Semen Descurainiae) 0.8g, Semen zanthoxyli 0.4g, Cordyceps 0.7g, Semen Sinapis Albae 0.8g.
Embodiment 2: artificial Calculus Bovis 1.6g, Thallus Laminariae (Thallus Eckloniae) 0.9g, Sargassum 0.9g, Semen Pharbitidis 0.9g, Herba Solani Nigri 1.6g, Cortex Cinnamomi 0.9g, Semen Lepidii (Semen Descurainiae) 1.6g, Semen zanthoxyli 0.8g, Cordyceps 1.3g, Semen Sinapis Albae 1.6g.
Embodiment 3: artificial Calculus Bovis 1.25g, Thallus Laminariae (Thallus Eckloniae) 1.6g, Sargassum 1.6g, Semen Pharbitidis 1.6g, Herba Solani Nigri 1.25g, Cortex Cinnamomi 1.6g, Semen Lepidii (Semen Descurainiae) 1.25g, Semen zanthoxyli 0.6g, Cordyceps 1g, Semen Sinapis Albae 1.25g.
Claims (1)
1. Chinese medicine for the treatment of cancerous ascites pleural fluid; it is characterized in that: it is made up of the component of following parts by weight proportioning: the artificial Calculus Bovis 0.8～1.6; Thallus Laminariae (Thallus Eckloniae) 0.5～0.9, Sargassum 0.5～0.9, Semen Pharbitidis 0.5～0.9; Herba Solani Nigri 0.8～1.6; Cortex Cinnamomi 0.5～0.9, Semen Lepidii (Semen Descurainiae) 0.8～1.6, Semen zanthoxyli 0.4～0.8; Cordyceps 0.7～1.3, Semen Sinapis Albae 0.8～1.6.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008100102419A CN101496851A (en) | 2008-01-28 | 2008-01-28 | Chinese medicine for treating carcinous pleural fluid and ascites |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2008100102419A CN101496851A (en) | 2008-01-28 | 2008-01-28 | Chinese medicine for treating carcinous pleural fluid and ascites |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101496851A true CN101496851A (en) | 2009-08-05 |
Family
ID=40944260
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2008100102419A Pending CN101496851A (en) | 2008-01-28 | 2008-01-28 | Chinese medicine for treating carcinous pleural fluid and ascites |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101496851A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101785819A (en) * | 2010-02-26 | 2010-07-28 | 泰一和浦（北京）中医药研究院有限公司 | Traditional Chinese medicine combination and preparation method thereof for hydrothorax treatment |
| CN103251863A (en) * | 2013-05-12 | 2013-08-21 | 张磊 | Chinese medicinal decoction for treating stagnant pathogen of Shaoyang type pleural effusion |
| CN104474344A (en) * | 2014-12-12 | 2015-04-01 | 韩军 | Chinese medicinal composition for treating pleural effusion and preparation method thereof |
-
2008
- 2008-01-28 CN CNA2008100102419A patent/CN101496851A/en active Pending
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101785819A (en) * | 2010-02-26 | 2010-07-28 | 泰一和浦（北京）中医药研究院有限公司 | Traditional Chinese medicine combination and preparation method thereof for hydrothorax treatment |
| CN101785819B (en) * | 2010-02-26 | 2011-09-14 | 泰一和浦（北京）中医药研究院有限公司 | Traditional Chinese medicine combination and preparation method thereof for hydrothorax treatment |
| CN103251863A (en) * | 2013-05-12 | 2013-08-21 | 张磊 | Chinese medicinal decoction for treating stagnant pathogen of Shaoyang type pleural effusion |
| CN103251863B (en) * | 2013-05-12 | 2014-09-24 | 张磊 | Chinese medicinal decoction for treating stagnant pathogen of Shaoyang type pleural effusion |
| CN104474344A (en) * | 2014-12-12 | 2015-04-01 | 韩军 | Chinese medicinal composition for treating pleural effusion and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102688420B (en) | Traditional Chinese medicine decoction for treating psoriasis | |
| CN104940784A (en) | Traditional Chinese medicine composition for treating chronic gastritis | |
| CN102526670A (en) | Traditional Chinese medicinal composition for treating cholecystitis and preparation method thereof | |
| CN101496851A (en) | Chinese medicine for treating carcinous pleural fluid and ascites | |
| CN104857454B (en) | A kind of traditional Chinese herbal decoction for treating Severe Acute Pancreatitis SAP | |
| CN104399040A (en) | Drug for treating gastrectasia and preparation method thereof | |
| CN105214067A (en) | A kind of medicine for the treatment of cancer patients diarrhoea | |
| CN101513508A (en) | Chinese medicament for treating breast cancer, and preparation method thereof | |
| CN104623605A (en) | Traditional Chinese medicine capable of treating breast cancer | |
| CN104491316B (en) | A kind of Chinese medicine preparation for the treatment of deficiency of QI in middle-JIAO type hyperplasia of prostate | |
| CN103446574B (en) | Medicine for curing constipation and obesity | |
| CN114732883B (en) | Traditional Chinese medicine composition for strengthening spleen and tonifying stomach as well as preparation method and application thereof | |
| CN106334155A (en) | Traditional Chinese medicine composition for treating arterial thyromegaly and preparation method thereof | |
| CN104587246B (en) | A kind of Chinese medicine preparation for treating epigastric pain and preparation method thereof | |
| CN104887949B (en) | A kind of Chinese medicine preparation for the treatment of DCM (dilated cardiomyopathy) and preparation method thereof | |
| CN105664113A (en) | Traditional Chinese medicine for treating lung cancers | |
| CN105617276A (en) | Medicine composition for treating rectal prolapse | |
| CN105079771A (en) | Traditional Chinese medicine composition for treating postoperatively adhesive intestinal obstruction | |
| CN105169199A (en) | Traditional Chinese medicinal composition for treating functional dyspepsia with syndrome of liver-stomach disharmony | |
| CN103690901A (en) | Traditional Chinese medicine for treating cholelithiasis and preparation method thereof | |
| CN104840864A (en) | Traditional Chinese medicine preparation for treating infantile diarrhea caused by spleen deficiency | |
| CN104721786A (en) | Traditional Chinese medicine preparation for treating intrahepatic cholestasis of pregnancy and preparation method of traditional Chinese medicine preparation | |
| CN103705787A (en) | Chinese medicine preparation for treating myocarditis | |
| CN104399010A (en) | Traditional Chinese medicinal capsule for nursing and treating lymphoma and preparation method of traditional Chinese medicinal capsule | |
| CN104306686A (en) | Externally applied medicine for treating leukoderma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20090805 |